B 细胞淋巴瘤的新兴治疗选择。
Emerging treatment options for B-cell lymphomas.
机构信息
Presented by Andrew D. Zelenetz, MD, PhD, Vice Chair, Medical Informatics, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Professor of Medicine at Weill Medical College of Cornell University, New York, New York.
出版信息
J Natl Compr Canc Netw. 2015 May;13(5 Suppl):666-9. doi: 10.6004/jnccn.2015.0198.
As targeted therapy in B-cell lymphomas rapidly expands beyond anti-CD20 monoclonal antibodies, many newer types of agents are in various stages of development. During his presentation at the NCCN 20th Annual Conference, Dr. Andrew D. Zelenetz explored many of them, including the newer immunoconjugates, the Bruton's tyrosine kinase inhibitor ibrutinib, agents targeting apoptosis such as venetoclax (ABT-199), the immunomodulator lenalidomide, and novel immune checkpoint inhibitors such as nivolumab. To improve outcomes in patients with B-cell lymphomas, these therapies either target the tumor cells and their pathways or focus on the microenvironment and immune modulation.
随着针对 B 细胞淋巴瘤的靶向治疗迅速超越抗 CD20 单克隆抗体，许多新型药物正处于不同的开发阶段。在 NCCN 第 20 届年会上，Andrew D. Zelenetz 博士探讨了其中的许多药物，包括新型免疫偶联物、布鲁顿酪氨酸激酶抑制剂伊布替尼、靶向凋亡的药物如 venetoclax（ABT-199）、免疫调节剂来那度胺以及新型免疫检查点抑制剂如 nivolumab。为了改善 B 细胞淋巴瘤患者的预后，这些治疗方法要么针对肿瘤细胞及其通路，要么聚焦于微环境和免疫调节。
Zotero 插件